Current treatments and emerging therapeutic approaches in male erectile dysfunction

BJU International, Supplement

Volumn 88, Issue 3, 2001, Pages 11-17

  Hatzichristou, D G ^a   Pescatori, E S ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Hesparia Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; IXENE; PHENTOLAMINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL; YOHIMBINE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DYSPEPSIA; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; HYPOTENSION; MYALGIA; NAUSEA; PENIS ERECTION; PHYSIOLOGY; PRIORITY JOURNAL; RHINITIS; SEXUALITY; SYNCOPE; VASCULAR SURGERY; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; ALPROSTADIL; APOMORPHINE; HUMANS; HYPOGONADISM; IMIDAZOLES; IMPOTENCE; MALE; PENILE IMPLANTATION; PHYSICAL THERAPY MODALITIES; PIPERAZINES; PSYCHOTHERAPY; SULFONES; TESTOSTERONE; TRIAZINES; VACUUM; VASCULAR SURGICAL PROCEDURES; VASODILATOR AGENTS; YOHIMBINE;

EID: 0034797293     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-4096.2001.123.x     Document Type: Article

References (54)

1. Preface
2. Current treatment and future perspectives for erectile dysfunction
3. Clinical evaluation and the doctor-patient dialogue
4. Impotence: A patient's goal directed approach to treatment
5. Recommendations of the 1st International Consultation on Erectile Dysfunction
6. NIH Consensus Conference: Impotence
7. Contextual approaches to the physiology and classification of erectile function, erectile dysfunction, and sexual arousal
8. Endocrine and metabolic aspect including treatment
9. Prolactin and testosterone: Their role in male sexual function
10. Relationship between sleep-related erections and testosterone levels in men
11. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men
12. Central neuropharmacological agents and mechanisms in erectile dysfunction: The role of dopamine
13. Sildenafil: A selective phosphodiesterase (PDE) 5 inhibitor in the treatment of erectile dysfunction (ED)
14. Oral sildenafil in the treatment of erectile dysfunction
15. Three-year update of sildenafil citrate (Viagra) efficacy and safety
16. Efficacy safety, and patient acceptance of sildenafil as treatment for erectile dysfunction
17. Treatment of erectile dysfunction with sildenafil
18. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment
19. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man
20. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction
21. Sildenafil (Viagra) and ophthalmology
22. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease
23. Recovery of erectile function by the oral administration of apomorphine
24. Apomorphine an update of clinical trial results
25. Efficacy of apomorphine SL in erectile dysfunction
26. Oral non-endocrine treatment
27. Oral and topical treatment of erectile dysfunction: Present and future
28. Oral phentolamine: An alpha-1 and alpha-2 selective adrenergic receptor antagonist for the treatment of erectile dysfunction
29. Local pharmacological treatment modalities
30. The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction, and their partners
31. Treatment of men with erectile dysfunction with transurethral alprostadil
32. Intracavernosal therapy
33. Review article. The rationale for prostaglandin E1 in erectile failure: A survey of world-wide experience
34. Penile fibrosis during 10 months of intracavernosal therapy with alprostadil (Caverject™)
35. Penile fibrosis in intracavernosal prostaglandin E1 injection therapy for erectile dysfunction - Comment
36. 1) in patients with erectile dysfunction
37. Self-injection devices for intracavernosal pharmacotherapy: Operational classification and safety considerations
38. Sildenafil versus intracavernosal injection: Efficacy and preference in patients on intracavernous injection for more than 1 year
39. IC351 enhances NO-mediated relaxation of human and trabecular penile smooth muscle
40. On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunction
41. On-demand administration of IC351 is effective and well tolerated in men with mild-to-severe erectile dysfunction
42. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: A RigiScan and pharmacokinetic study
43. Vardenafil, a new highly selective PDE5 inhibitor, improves erectile function irrespective of the baseline severity and etiology of ED or age of patient
44. Antagonism of rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway
45. Potential application of gene therapy for the treatment of erectile dysfunction
46. Surgical treatment and mechanical devices
47. Patient acceptance of and satisfaction with an external negative pressure device for impotence
48. Long-term results with vacuum constriction device
49. Treating erectile dysfunction with vacuum tumescence device; a retrospective analysis of acceptance and satisfaction
50. Penile microvascular arterial bypass surgery: Indications and surgical considerations
51. Clinical guidelines panel on erectile dysfunction: Summary report on the treatment of organic erectile dysfunction
52. Infectious complications of penile prosthetic implants
53. New therapies and delivery mechanisms for treatment of erectile dysfunction